Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Public ClinicalTrials.gov record NCT01193244. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a randomized, double-blind, multicenter, phase 3 study evaluating orteronel (TAK-700) plus prednisone compared with placebo plus prednisone in the treatment of men with progressive, chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC)
Study identification
- NCT ID
- NCT01193244
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,560 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2010 (Actual)
- Primary completion
- Jan 1, 2014 (Actual)
- Completion
- Apr 7, 2016 (Actual)
- Last update posted
- May 17, 2017
2010 – 2016
United States locations
- U.S. sites
- 48
- U.S. states
- 27
- U.S. cities
- 48
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Anchorage | Alaska | — | — |
| Not listed | Tucson | Arizona | — | — |
| Not listed | Duarte | California | — | — |
| Not listed | Highland | California | — | — |
| Not listed | Orange | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | San Francisco | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Deerfield Beach | Florida | — | — |
| Not listed | Fort Myers | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Port Saint Lucie | Florida | — | — |
| Not listed | Jeffersonville | Indiana | — | — |
| Not listed | Kansas City | Kansas | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | Boston | Massachusetts | — | — |
| Not listed | Lansing | Michigan | — | — |
| Not listed | Duluth | Minnesota | — | — |
| Not listed | Corinth | Mississippi | — | — |
| Not listed | Columbia | Missouri | — | — |
| Not listed | Jefferson City | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Hackensack | New Jersey | — | — |
| Not listed | East Syracuse | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Raleigh | North Carolina | — | — |
| Not listed | Kettering | Ohio | — | — |
| Not listed | Tualatin | Oregon | — | — |
| Not listed | Hershey | Pennsylvania | — | — |
| Not listed | Lancaster | Pennsylvania | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Piitsburgh | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Chattanooga | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Amarillo | Texas | — | — |
| Not listed | Bedford | Texas | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Denton | Texas | — | — |
| Not listed | Tyler | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 192 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01193244, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 17, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01193244 live on ClinicalTrials.gov.